Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | — |
Received First Dose on June 4th 2024, and Here for the Second Dose Now; Initial report received on 07-Feb-2025. A pharmacist reported that a 50-year-old female received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and has not received the second dose yet. No medical history or concomitant medications were reported. On 04-Jun-2024, the patient received dose 1 of a hepatitis B vaccine HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). On 07-Feb-2025, 248 days after having been vaccinated with HEPLISAV-B, the patient presented to a pharmacy to receive the second dose of HEPLISAV-B. The pharmacist inquired if the patient needed to restart the vaccine series as the first dose was received more than one month prior. The patient has not received the second dose of HEPLISAV-B yet but was in the pharmacy to receive the second dose. No adverse reactions were reported. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.